$GOSS News
Last published 2d ago
- 2d agoGOSSGossamer Bio, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2d agoGOSSGossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business UpdateBusiness WireSAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the third ...
- 1mo agoGOSSGossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial HypertensionBusiness Wire– NDA Supported by the Phase 3 PROSERA Study, Phase 2 TORREY Study and Additional Supportive Analyses – Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a clinical-stage
- 1mo agoGOSSGossamer Bio Appoints Greg Ciongoli to Board of DirectorsBusiness WireGossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
- 2mo agoGOSSGossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock SplitBusiness WireGossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary
- 2mo agoGOSSGossamer Bio Announces 1-for-80 Reverse Stock SplitBusiness WireGossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary
- 2mo agoGOSSGossamer Bio to Present at Cantor Global Healthcare ConferenceBusiness WireGossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
- 2mo agoGOSSGossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA ApprovalBusiness Wire– $150 Million of Committed Capital: $25 Million Funded Upfront at Initial Closing, Plus an Additional $125 Million that Funds Upon FDA Acceptance of the Seralutinib NDA in PAH – – Potential for Up to an Additional
- 3mo agoGOSSGossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business UpdateBusiness Wire- NDA Submission for Seralutinib in PAH On Track for September 2026 Following Receipt of Pre-NDA Type B Meeting Minutes - - Gossamer Reacquired Worldwide Development and Commercial Rights to Seralutinib from Chiesi,
- 3mo agoGOSSGossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business UpdateBusiness Wire– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH –– Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential
- 4mo agoGOSSGossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase WarrantsBusiness WireGossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial
- 4mo agoGOSSGossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible NotesBusiness WireGossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and
- 5mo agoGOSSGossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible NotesBusiness WireGossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and
- 5mo agoGOSSGossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible NotesBusiness WireGossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and
- 5mo agoGOSSGossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder SupportBusiness WireGossamer Bio, Inc. (NASDAQ:GOSS) (the "Company"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
- 5mo agoGOSSGossamer Bio Announces First Quarter 2026 Financial Results and Provides Business UpdateBusiness Wire- FDA Confirms In-Person Pre-NDA Type B Meeting in Mid-June - - Positive PROSERA CT FRI Results Demonstrated Multiple Statistically Significant Treatment Effects, Including Novel Signals Correlated with Clinical
- 6mo agoGOSSGossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026Business WireGossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
- 6mo agoGOSSThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 1, 2026 in Gossamer Bio, Inc. Lawsuit - GOSSPR NewswireThe Gross Law Firm issues the following notice to shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS). Shareholders who purchased shares of GOSS during ...
- 8mo agoGOSSGossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate UpdateBusiness Wire- Following PROSERA Phase 3 topline results, the Company is focused on evaluating the totality of the dataset, engaging with the FDA, and assessing strategic options and capital allocation - - Enrollment in the Phase
- 8mo agoGOSSBREAKING: Gossamer Bio Investors Should Contact Block & Leviton to Potentially Recover Losses After Shares Fall Over 75%GlobeNewswireBOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Gossamer Bio, Inc. (NASDAQ:GOSS) for potential securities law violations. Investors who have lost money in their Gossamer Bio, Inc.
- 8mo agoGOSSGossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial HypertensionBusiness Wire- Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025 - - At week 24, patients
- 11mo agoGOSSGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireGossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
- 11mo agoGOSSGossamer Bio to Participate in Upcoming Investor ConferencesBusiness WireGossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
- 1y agoGOSSGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireGossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
- 1y agoGOSSGossamer Bio to Participate in Upcoming Investor ConferencesBusiness WireGossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
- 1y agoGOSSGossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business UpdateBusiness Wire- Topline Results from PROSERA Phase 3 Expected in February 2026 - - First Site Activated for Registrational Phase 3 SERANATA Study in PH-ILD - - Cash, cash equivalents and marketable securities totaled $180 million
- 1y agoGOSSGossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary HypertensionBusiness Wire- RT234 is an investigational inhaled, as needed (PRN) vardenafil formulation for PAH and PH-ILD, where no on demand treatments exist -
- 1y agoGOSSGossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025Business Wire- One Oral and Four Poster Presentations Highlight Seralutinib's Potential Across Pulmonary Hypertension and Fibrotic Lung Disease - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused
- 1y agoGOSSGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireGossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
- 1y agoGOSSGossamer Bio to Present at Upcoming Investor ConferencesBusiness WireGossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
- 1y agoGOSSGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireGossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
- 1y agoGOSSGossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business UpdateBusiness Wire- Topline Results from PROSERA Phase 3 Expected in February 2026 - - First Site Activations for Planned Registrational Phase 3 SERANATA Study in PH-ILD Expected in the Fourth Quarter of 2025 - - Cash, cash
- 1y agoGOSSGossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAHBusiness Wire- Enrollment Completed in Ongoing Registrational PROSERA Phase 3 Study in PAH - - Topline Results Announcement from PROSERA Phase 3 Expected in February 2026 - - Blinded Preliminary Baseline Characteristics Align
- 1y agoGOSSGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireGossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
- 1y agoGOSSGossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA StudyBusiness Wire- Enrollment Completion for Ongoing Registrational PROSERA Phase 3 Study in PAH Expected in Early June; New Patient Screening Closed - - Topline Results Announcement from PROSERA Phase 3 Expected in February 2026 - -
- 1y agoGOSSGossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025Business WireGossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
- 1y agoGOSSGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireGossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
- 1y agoGOSSGossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International ConferenceBusiness WireGossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
- 1y agoGOSSGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireGossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
- 1y agoGOSSGossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business UpdateBusiness Wire- PROSERA Phase 3 in PAH on Track for Topline Data Readout in Fourth Quarter of 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Second Half of 2025 - - Seralutinib Receives Orphan Drug Designation
- 1y agoGOSSGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireGossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
- 1y agoGOSSGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireGossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
- 1y agoGOSSGossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual CongressBusiness WireGossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
- 1y agoGOSSGossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual CongressBusiness Wire- Gossamer to Present Preclinical Evidence of Synergistic Treatment Effect from Combination Seralutinib & Sotatercept in Models of PAH - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company
- 1y agoGOSSGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireGossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
- 2y agoGOSSGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireGossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
- 2y agoGOSSGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireGossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
- 2y agoGOSSGossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024Business Wire- Additional Phase 2 TORREY Open-Label Extension Data to be Presented in Vienna - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of
- 2y agoGOSSGossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire- $354 Million in Cash, Cash Equivalents & Marketable Securities, as of June 30, 2024 - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization
- 2y agoGOSSGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireGossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary